PPD beefs up its therapeutics team with new leadership

Pushpin showing North Carolina on a map
Darell Heiselman, D.O., will lead PPD’s cardiovascular and critical care niches, while David Klein, M.D., has been charged with overseeing endocrinology, metabolism and diabetes. (Getty/Creative RF)

Pharmaceutical Product Development, a North Carolina-based CRO, is adding more punch to its therapeutics offerings with new leadership overseeing a number of prime areas.

Darell Heiselman, D.O., will lead PPD’s cardiovascular and critical care niches, while David Klein, M.D., has been charged with overseeing endocrinology, metabolism and diabetes.

“In their new roles, Darell and David will help develop cross-functional, integrated product development plans and assist with the design of clinical trials to provide therapeutic, protocol and site development expertise for our clients and their product,” Rob Dow, PPD’s chief medical officer, said in a statement.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Heiselman has been named vice president of global product development. In his 23 years of practice, he developed a critical care center of excellence and performed more than 60 clinical trials in critical care, cardiology, nutritional support and stroke. Before PPD, Heiselman spent 11 years at Eli Lilly as a clinical research physician.

Klein, who is board-certified in pediatrics with a subspecialty board certification in pediatric endocrinology, has also been named a vice president of global product development. He has extensive experience managing diabetes and endocrine clinical trials, as well as trials in the therapeutic areas of pediatrics, rare disease, obesity, lipid metabolism, nonalcoholic steatohepatitis and celiac disease. He previously served as medical director at Medpace and as senior director of clinical development at Mannkind Corp.

Read more on

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.